Xeloda

Xeloda® (capecitabine) is a Prescription Medicine used to treat bowel and rectum (colorectal), oesophagus, stomach and breast cancer. Xeloda may be used alone or in combination with other cancer medicines.Xeloda should not be taken if you: have had a reaction in the past to any of the ingredients in Xeloda, have severe kidney disease, are taking a medicine called sorivudine or brivudine, or have allergies to other fluoropyrimidine medicines such as 5-fluorouracil, have dihydropyrimidine dehydrogenase (DPD) deficiency. Tell your doctor if you: are pregnant or breastfeeding, have heart, liver, or kidney disease; diarrhoea or dehydration. Signs of dehydration include dry skin, dark coloured urine, thirst, weakness or fatigue, loss of appetite. Possible unwanted effects: Common: tiredness, weakness; rash, dry or itchy skin; abdominal (gut) pain; fever; constipation; headache; dizziness; reduced appetite, weight loss; hair loss; watery or irritated eyes; taste disturbance; indigestion; dry mouth; nail disorders; sore throat, cough, nose bleeds; shortness of breath; muscle and joint pain. Serious (common): severe diarrhoea, nausea, or vomiting; pain, redness, swelling of hands/feet (hand-foot-syndrome); pain, redness, swelling or sores in the mouth (stomatitis). Serious (rare): chest pain; irregular heart beat; confusion; poor balance or lack of co-ordination; blood in the faeces; signs of infection (fever, redness) or liver disease (yellow eyes/skin). Ask your oncologist if Xeloda is right for you. Use strictly as directed. If symptoms continue or you experience side-effects or would like further information, please talk to your oncologist or visit www.medsafe.govt.nz for Xeloda Consumer Medicines Information. Xeloda (150mg and 500mg tablets) is a funded medicine for patients who meet pre-defined criteria. A prescription charge and normal oncologist’s fees may apply.

For more information please view the Xeloda Consumer Medicines Information. Access to this site is subject to the terms in our Legal Statement; you accept these terms by continuing to access this site. ID454/TAPS:NA3760/2009DEC